April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
SOP for removal of PVD induced vitreous opacities
Author Affiliations & Notes
  • Frank HJ Koch
    House 7c, University Eye Clinic, Frankfurt / M., Germany
  • Svenja Deuchler
    House 7c, University Eye Clinic, Frankfurt / M., Germany
  • Pankaj Singh
    House 7c, University Eye Clinic, Frankfurt / M., Germany
  • Thomas Kohnen
    House 7c, University Eye Clinic, Frankfurt / M., Germany
  • Henrik Schaefer
    House 7c, University Eye Clinic, Frankfurt / M., Germany
  • Footnotes
    Commercial Relationships Frank Koch, Insight Instruments, Inc. (C); Svenja Deuchler, None; Pankaj Singh, None; Thomas Kohnen, None; Henrik Schaefer, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2322. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frank HJ Koch, Svenja Deuchler, Pankaj Singh, Thomas Kohnen, Henrik Schaefer; SOP for removal of PVD induced vitreous opacities. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2322.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To present the concept of a new standard operating procedure (SOP) enhancing the diagnostic examinations and surgical procedures to the exacting needs of patients suffering from symptomatic vitreous opacities.

Methods: A retrospective study of 102 patients (117 eyes) was performed to evaluate patient satisfaction associated with symptomatic vitreous opacaties. We perform an interactive evaluation to detect the clinical significance of patient’s opacities using (1) quality-of-life questionaires (the NEI-VFQ-25 and a customized FFQ-22 test), (2) pictures drawn by hand on paper and (3) into a scanner and (4) a contrast vision test (CVA). Before surgery, we use biomicroscopy, OCT and eventually ultrasonography to select the preferred device for performing a core pars plana vitrectomy (cPPV) in the individual eye: (a) single-incision-site Intrector®, (b) a two-incision-site Retrector® or (c) a three-port cannula setup.1

Results: 117 eyes were followed over 24 months. No eye showed clinically significant lens changes post cPPV. 95% were satisfied after the initial intervention and 100% after the second one. In one eye we found a retinal hole with a limited retinal detachment. In 86% of cases, the response to a single or two-site 23 g cPPV was immediate. 14% noticed visual perception changes over a time period of 90-120 days. In a subgroup analysis (n = 20), the NEI-VFQ-25 and the FFQ-22 correlated well preoperatively (rho = 0.510, p < 0.05) and postoperatively (rho = 0.476, p < 0.05). The FF-22 described the changes in quality of life (p = 0.001289), wellbeing (p = 0.072834) and the type of vision disorder (p = 0.000082) with significant changes in 85% of eyes (Wilcoxon-matched-pair-test: p = 0.000082). When quality of vision was recorded with the CVA, remarkable details about the vision under mesopic and glare conditions were obvious.

Conclusions: PVD induced vitreous opacities have a significant impact on the patients quality of life.2 As part of this SOP, performing all tests contributed substantially to the patient’s satisfaction and subsequent decision regarding removal of symptomatic vitreous opacifications in their second eye. 1 Frank H. Koch, MD, PhD; Michael J. Koss, MD, FEBO. Microincision Vitrectomy Procedure Using Intrector Technology. Arch Ophthalmol. 2011;129:1599-1604 2 Jerry Sebag. Am. J. Ophthalmology, 2011; 152 Editorial , 3e.1-4 e.1

Keywords: 762 vitreoretinal surgery • 697 retinal detachment • 445 cataract  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.